Efficacy of TIGIT in the cancer immune cycle
10.3760/cma.j.issn.1008-6315.2018.01.019
- VernacularTitle:免疫抑制性受体TIGIT在癌症免疫周期中的作用
- Author:
Yusheng ZHANG
1
;
Yaoguang CHEN
;
Sining LI
;
Jian WANG
Author Information
1. 广东医科大学研究生学院
- Keywords:
TIGIT;
Tumor immune cycle;
Dendritic cell;
Natural killer cell;
T cell
- From:
Clinical Medicine of China
2018;34(1):89-91
- CountryChina
- Language:Chinese
-
Abstract:
Immunotherapy is a therapeutic method that uses the immune system to inhibit tumor activity and kill tumor cells.It has been proved to be effective in the treatment of various malignant tumors.In general, the immune system can recognize and kill the abnormal cells,while the tumor cells can produce a variety of mechanisms to inhibit the immune system,resulting into the incomplete death of the cells.TIGIT is a type of inhibitory receptor containing T cell immunoglobulin and immunoreceptor protein tyrosine inhibitory motif (ITIM)protein domain.This paper discusses the role of TIGIT in limiting antitumor responses and reviews the mechanisms of action during the cancer immunity cycles.
